Substitute for form 1449A/PTO				I	Complete if Known				
INFORMATION DISCLOSURE					Application Number	20859			
<b>∠\' 4</b> \\									
(line among about if necessary)				\	Filing Date	February 21, 2002 with Express			
(Use several sheets if necessary)				<u>μ</u>		Mail Label No. EL912162005			
10N 0 0 2 5						US			
		_\_			First Name Inventor	Brandt, M. et al.			
Sheet 1 of 1									
U.S. PATENT DOCUMENTS									
Examiner Initials'	Cite No.1	U.S. Patent Document		Name of Patentee or Applicant of		Date of Publication of Cited			
		Kind Code <sup>2</sup> Number (if known)							
					Cited Document		document		
						MM-DD-YYYY			
4	<b>A1</b>	5,977,	310		Namiki, et al.		November 2, 19	99	
			FC	REIGN PA	ATENT DOCUMENTS				
	Cite	Foreign Patent Document					ate of Publication of	T6	
Examiner		Office Number Kind Code			Name of Patentee or	}	Cited Document		
Initials'	No.1	Onice	Number4	(if known)	Applicant of Cited		MM-DD-YYYY		
					Document				
	<del>-B1</del>	EP 0.8	16 381 7	Displic	Jule for (292)	Jan	uary 7, 1998	-	
be	<b>B2</b>	WO 94/13322			June 23, 1994				
La	<b>B3</b>	WO 93/23541				No	vember 25, 1993		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
LL	C1 V			
	/C2	Date, K., et al., Oncogene (1998) Vol. 17 pgs. 3045-3054 Duplical	E/8	72
4	C3 ~	Kuba, K., et al. Cancer Research (2000) Vol. 60, pgs. 6737-6743		/
H	C4	Vernatsu Y., et al., Journal of Pharmaceutical Sciences (1/99), Vol. 88 No. 1, pgs. 131-135		, ,
-	-C5	Gaertner, H., et al., Bioconjugate Chem. (1996) Vol. 7 pgs. 38-44 DOF.	Treat	1(8
H	C6 /	Francis, G.E., et al., International Journal of Hematology, Vol. 68 (1998) pgs. 1-18		
1	C7	Tsutsumi, Y. et al. Thrombosis & Haemostasis Vol. 77, No. 1 (1997) pgs. 168-173		
	C8	Tsutsumi, Y. et al., Proceedings of the National Academy of Sciences of the United States, Vol. 97, No. 15 (7/18/00) pgs. 8548-8553)		
	C9 -	Heinzerling, L., et al., Dermatology (2000) Vol. 201, pgs. 154-157		
	C10	Tsutsumi, Y. et al., Journal of Pharmacology & Experimental Therapeutics Vol. 278 No. 3 (1996) pgs. 1006-1011		
	C11	Reddy, R., et al. Annals of Pharmacotherapy Vol. 34, No. 7-8 (7/2000) pgs. 915-923		
		Bailon, P., Bioconjugate Chem. Vol. 12 (02/16/2001) pgs. 195-202		
20	C13	Parr, C., et al., Int. J. Cancer Vol. 85 (2000) pgs. 563-570		

Examiner	Lasan	11.	Date Considered	3/10/00
Signature	La Juliana	Char or		11906

\*EXAMDRE: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. 25ce attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation or abstract is attached.